Major Milestone with First Sales of Remplir in Singapore
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Orthocell Ltd has announced its first sales of the Remplir peripheral nerve repair device in Singapore, marking a significant milestone in its commercialization efforts. The initial sales occurred ahead of a planned market launch, indicating strong demand and the effectiveness of its distribution partner, Device Technologies Asia. The company is also preparing for expansion into the U.S. market with expected regulatory approvals in the near future. Orthocell maintains a strong financial position with substantial cash reserves to support its growth initiatives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Orthocell
- Outstanding Remplir Study Results Pave Way for FDA Clearance
- Distributor Signed, Remplir Sales in Singapore to Commence
- Key Executives Appointed to Drive Remplir US Sales
- Orthocell completes $17m Placement
- $17m Placement to Drive Further Growth as US Approval Nears
Later from Orthocell
- US FDA Application Submitted for Remplir as US Launch Nears
- Third Consecutive Quarter of Record Revenue for Orthocell
- Orthocell Receives $3.18 million R&D Tax Refund
- S&P DJI Announces March 2025 Quarterly Rebalance
- Regulatory approval to commence Striate sales in Singapore
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell